Brokers Set Expectations for STOK FY2029 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Analysts at Wedbush issued their FY2029 earnings estimates for shares of Stoke Therapeutics in a research note issued to investors on Tuesday, January 7th. Wedbush analyst L. Chico forecasts that the company will earn ($0.41) per share for the year. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.03) per share.

A number of other research analysts also recently weighed in on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Needham & Company LLC restated a “buy” rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. Leerink Partners initiated coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an “outperform” rating and a $18.00 target price on the stock. Chardan Capital initiated coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $24.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $21.29.

Stoke Therapeutics Stock Down 3.8 %

Shares of STOK opened at $8.96 on Thursday. The company has a 50 day moving average of $12.05 and a 200-day moving average of $13.11. The stock has a market capitalization of $474.58 million, a P/E ratio of -4.27 and a beta of 0.95. Stoke Therapeutics has a twelve month low of $4.09 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Insider Transactions at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the sale, the insider now owns 51,277 shares in the company, valued at approximately $618,913.39. This trade represents a 16.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Jonathan Allan sold 9,696 shares of the company’s stock in a transaction dated Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now owns 35,142 shares in the company, valued at approximately $449,114.76. This trade represents a 21.62 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 62,849 shares of company stock worth $809,421. 11.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

A number of large investors have recently made changes to their positions in STOK. Quest Partners LLC bought a new stake in Stoke Therapeutics in the 2nd quarter valued at $29,000. Intech Investment Management LLC acquired a new stake in shares of Stoke Therapeutics during the third quarter worth $160,000. The Manufacturers Life Insurance Company boosted its position in shares of Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock valued at $189,000 after acquiring an additional 1,994 shares during the period. Mesirow Financial Investment Management Inc. acquired a new position in shares of Stoke Therapeutics in the third quarter valued at about $192,000. Finally, Profund Advisors LLC bought a new position in Stoke Therapeutics during the second quarter worth about $201,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.